- Home
- AVTX vs DOMH Comparison
AVTX vs DOMH Comparison
Compare AVTX & DOMH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- DOMH
- Stock Information
- Founded
- AVTX 2011
- DOMH 1967
- Country
- AVTX United States
- DOMH United States
- Employees
- AVTX N/A
- DOMH N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- DOMH Biotechnology: Pharmaceutical Preparations
- Sector
- AVTX Health Care
- DOMH Health Care
- Exchange
- AVTX Nasdaq
- DOMH Nasdaq
- Market Cap
- AVTX 138.8M
- DOMH 94.0M
- IPO Year
- AVTX 2015
- DOMH N/A
- Fundamental
- Price
- AVTX $11.12
- DOMH $6.01
- Analyst Decision
- AVTX Strong Buy
- DOMH
- Analyst Count
- AVTX 8
- DOMH 0
- Target Price
- AVTX $31.00
- DOMH N/A
- AVG Volume (30 Days)
- AVTX 171.6K
- DOMH 304.5K
- Earning Date
- AVTX 11-06-2025
- DOMH 11-07-2025
- Dividend Yield
- AVTX N/A
- DOMH 8.91%
- EPS Growth
- AVTX N/A
- DOMH N/A
- EPS
- AVTX N/A
- DOMH N/A
- Revenue
- AVTX $441,000.00
- DOMH $52,811,000.00
- Revenue This Year
- AVTX N/A
- DOMH N/A
- Revenue Next Year
- AVTX N/A
- DOMH N/A
- P/E Ratio
- AVTX N/A
- DOMH N/A
- Revenue Growth
- AVTX N/A
- DOMH 455.38
- 52 Week Low
- AVTX $3.39
- DOMH $0.83
- 52 Week High
- AVTX $16.00
- DOMH $13.58
- Technical
- Relative Strength Index (RSI)
- AVTX 61.13
- DOMH 48.86
- Support Level
- AVTX $9.54
- DOMH $5.90
- Resistance Level
- AVTX $12.41
- DOMH $7.18
- Average True Range (ATR)
- AVTX 1.05
- DOMH 0.45
- MACD
- AVTX -0.11
- DOMH -0.06
- Stochastic Oscillator
- AVTX 64.63
- DOMH 24.84
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc through its various subsidiaries, is currently engaged in wealth management, investment banking, securities sales and trading and asset management. The company operates in two reportable business segments: Dominari Financial and Legacy AIkido. The Dominari Financial reportable business segment represents the Company's broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. It generates the majority of its revenue from the Dominari Financial segment.